Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
Recent Articles By The Author
Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up
The two Hep C drugs are similar enough chemically to warrant caution.
Gilead Sciences Firing On All Cylinders
Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.
The Health Care Short Sales That Never Fit
Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.
Eli Lilly, Verastem and the Defenders of Shareholder Value
TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.
Onyx Pharma Must Start Delivering Profits
With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.
ObamaCare Upheld: Health Care Stock Winners and Losers
TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.
Arena Pharma And The Fat Lady's Song
Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.
Alkermes Needs to Build on Drug Delivery Success
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law
Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.
Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences
Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.